Shares of biotech firm Anavex Life Sciences Corp. (NASDAQ: AVXL) fell more than 17% in today’s trading session. This can be attributed to its Q4 earnings results.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The company currently has no sales, meaning that analysts are estimating its cash burn. Earnings per share came in at -$0.18, which was lower than the -$0.17 that was expected.
Is AVXL Stock a Good Investment?
AVXL stock has a Strong Buy consensus rating based on four Buys assigned in the past three months. The average AVXL stock price target of $39.25 implies almost 300% upside potential.
